[Anti-arrhythmia and electrophysiological effects of encainide in supraventricular tachycardias]. 1985

B Cassagneau, and J P Miquel, and J P Puel, and B Mordant, and A Kher, and J M Fauvel, and J P Bounhoure

In order to assess the electrophysiologic effects and anti-arrhythmia effects of encainide after acute IV injection and chronic oral therapy, a group of 10 patients (mean age 54) with recurrent supraventricular tachycardia was studied. Seven patients had more than 2 attacks per month, and supraventricular tachycardia (SVT) resulted in severe symptoms in the three remaining SVT was due to AV nodal re-entry in 6 patients and to concealed accessory pathway in 4. After a control study, SVT was initiated, and encainide (0.75 mg/kg) was infused intravenously in attempt to stop the tachycardia. A second study was achieved. After 4 days of oral therapy (25 or 50 mg T.I.D.) a third study was performed, including SVT initiation attempts. Encainide depressed conduction in all cardiac tissues, and this effect was more evident after oral administration. Antegrade I:I conduction cycle length increased of 13.9% (p less than 0.05), and the same parameter in retrograde conduction increased of 30.03% (p less than 0.05). IV injection interrupted 2 of 10 SVT only. However, after 30 minutes, 5 re-initiated SVT were nonsustained, and mean cycle length increased from 326 +/- 21 to 397 +/- 51 (p less than 0.01). After oral therapy, SVT was initiated in 4 of 10 patients, nonsustained in 3. During long term follow-up (one year or more), no severe adverse effect has been reported. Three patients are still experiencing short events of well-tolerated SVT. Hence, moderate or low doses or oral encainide may safely control recurrent supraventricular tachycardia.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006329 Heart Conduction System An impulse-conducting system composed of modified cardiac muscle, having the power of spontaneous rhythmicity and conduction more highly developed than the rest of the heart. Conduction System, Heart,Conduction Systems, Heart,Heart Conduction Systems,System, Heart Conduction,Systems, Heart Conduction
D006352 Heart Ventricles The lower right and left chambers of the heart. The right ventricle pumps venous BLOOD into the LUNGS and the left ventricle pumps oxygenated blood into the systemic arterial circulation. Cardiac Ventricle,Cardiac Ventricles,Heart Ventricle,Left Ventricle,Right Ventricle,Left Ventricles,Right Ventricles,Ventricle, Cardiac,Ventricle, Heart,Ventricle, Left,Ventricle, Right,Ventricles, Cardiac,Ventricles, Heart,Ventricles, Left,Ventricles, Right
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

B Cassagneau, and J P Miquel, and J P Puel, and B Mordant, and A Kher, and J M Fauvel, and J P Bounhoure
December 1983, Minerva medica,
B Cassagneau, and J P Miquel, and J P Puel, and B Mordant, and A Kher, and J M Fauvel, and J P Bounhoure
November 1990, International journal of cardiology,
B Cassagneau, and J P Miquel, and J P Puel, and B Mordant, and A Kher, and J M Fauvel, and J P Bounhoure
May 1985, Giornale italiano di cardiologia,
B Cassagneau, and J P Miquel, and J P Puel, and B Mordant, and A Kher, and J M Fauvel, and J P Bounhoure
June 1984, Arquivos brasileiros de cardiologia,
B Cassagneau, and J P Miquel, and J P Puel, and B Mordant, and A Kher, and J M Fauvel, and J P Bounhoure
August 1986, The American journal of cardiology,
B Cassagneau, and J P Miquel, and J P Puel, and B Mordant, and A Kher, and J M Fauvel, and J P Bounhoure
November 1983, Revista medica de Chile,
B Cassagneau, and J P Miquel, and J P Puel, and B Mordant, and A Kher, and J M Fauvel, and J P Bounhoure
December 1988, The American journal of cardiology,
B Cassagneau, and J P Miquel, and J P Puel, and B Mordant, and A Kher, and J M Fauvel, and J P Bounhoure
June 1983, JAMA,
B Cassagneau, and J P Miquel, and J P Puel, and B Mordant, and A Kher, and J M Fauvel, and J P Bounhoure
February 1984, British medical journal (Clinical research ed.),
B Cassagneau, and J P Miquel, and J P Puel, and B Mordant, and A Kher, and J M Fauvel, and J P Bounhoure
January 1981, Heart & lung : the journal of critical care,
Copied contents to your clipboard!